POINT OF CARE DIAGNOSTICS MARKET ANALYSIS

Point of Care Diagnostics Market, By Technology (Lateral Flow, Agglutination Assays, Flow-Through, Solid Phase, Biosensors), By Application (Cardio Metabolic Testing, Infectious Disease Testing, Nephrology Testing, Drugs of Abuse (DoA) Testing, Blood Glucose Testing, Pregnancy Testing, Cancer Biomarker Testing, Others), By End User (Hospitals, Diagnostic Laboratories, Home-Care Settings, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

On February 2024, A supplement in BMC Infectious Diseases on point-of-care testing for sexually transmitted infections (STIs) was launched on 29 February 2024. The supplement featured findings from the PRoSPeRo project, which was the largest field evaluation of STI diagnostics, coordinated by HRP and WHO, across 15 countries and 30 sites, involving over 17,000 participants.
In October 2023, QIAGEN obtained CE certification for its IVD kit and automated testing platform, NeuMoDx, significantly boosting the company’s revenue and market share.
In May 2023, Danaher Corporation launched the Dxl 9000 Access Immunoassay Analyzer, capable of performing up to 215 tests per hour, thereby expanding its point-of-care diagnostics portfolio.
In May 2023 BD received 510(k) clearance for its BD Kiestra Methicillin-resistant Staphylococcus aureus (MRSA) imaging application, which leverages AI software to expedite test results by automating the traditionally time-consuming process of analyzing bacterial growth on petri dishes.